01.13.20
Adare Pharmaceuticals and NLS Pharmaceutics have formed a collaboration to develop mazindol (MZD) CR product candidates for the treatment of narcolepsy and Attention Deficit Hyperactivity Disorder (ADHD).
The collaboration will utilize Adare’s proprietary modified release technologies. The enhanced collaborative formulations are intended to deliver an effective pharmacokinetic profile, and are expected to improve patient compliance and disease management. MZD is a norepinephrine reuptake inhibitor previously approved by the U.S. Food and Drug Administration for the treatment of obesity.
“We are excited to enter this collaboration with NLS to develop new formulations for MZD, which will provide enhanced patient centric solutions for central nervous system disorders,” said Ajay Damani, vice president, pharmaceutical technologies, Adare. “Our expertise with product development and manufacturing of customized release and multiparticulate dosage forms makes this an ideal partnership for Adare.”
Alex Zwyer, chief executive officer and co-founder, NLS, said, “We believe that the partnership with Adare provides us with the expertise with respect to formulation that may help us to efficiently develop our product candidates. We value the experience Adare offers as part of our supply chain, and the new intellectual property applied to our product candidates. We anticipate success for both parties in this collaboration.”
The collaboration will utilize Adare’s proprietary modified release technologies. The enhanced collaborative formulations are intended to deliver an effective pharmacokinetic profile, and are expected to improve patient compliance and disease management. MZD is a norepinephrine reuptake inhibitor previously approved by the U.S. Food and Drug Administration for the treatment of obesity.
“We are excited to enter this collaboration with NLS to develop new formulations for MZD, which will provide enhanced patient centric solutions for central nervous system disorders,” said Ajay Damani, vice president, pharmaceutical technologies, Adare. “Our expertise with product development and manufacturing of customized release and multiparticulate dosage forms makes this an ideal partnership for Adare.”
Alex Zwyer, chief executive officer and co-founder, NLS, said, “We believe that the partnership with Adare provides us with the expertise with respect to formulation that may help us to efficiently develop our product candidates. We value the experience Adare offers as part of our supply chain, and the new intellectual property applied to our product candidates. We anticipate success for both parties in this collaboration.”